Released Aug 6, 2026, after the close
10-Q filed Aug 6, 2026, 37 days after period end · 0001493152-26-036424
Q2 2026 · 10-Q
Revenue—
Net Income-$4.01M-$4.01M N/M vs Q2 2025N/M vs Q1 2026
EPS Diluted-$3.40-$3.40 N/M vs Q2 2025N/M vs Q1 2026
Operating Income-$4,104,000N/M
Operating Cash Flowderived-$4,152,000N/M
Free Cash Flowderived-$4,155,000—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | — | — | $47.00K | — |
| Net Income | -$4.01M | -$3.14M | -$5.53M | -$4.51M |
| EPS Diluted | -$3.40 | -$15.19 | -$15.34 | -$0.85 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR